Healthequity (HQY) Price to Sales (2014 - 2026)

Healthequity has reported Price to Sales for 13 years, with the latest figure at 23.78 in Q3 2026.

• On a quarterly basis, Price to Sales fell 7.56% year-over-year to 23.78 in Q3 2026; TTM through Jul 2026 was 6.12, a 7.3% decrease from a year earlier, with the FY2026 full-year figure at 5.54, down 30.38% from the prior year.
• Price to Sales was 23.78 for Q3 2026 at Healthequity, up from 19.41 in the prior quarter.
• The five-year high for Price to Sales was 30.64 in Q1 2025, with the low at 18.69 in Q2 2023.
• Average Price to Sales over 5 years is 24.02, with a median of 23.87 recorded in 2024.
• The sharpest annual moves came in 2022 and 2024: Price to Sales plunged 35.73% in 2022, then rose 27.74% in 2024.
• Over 5 years, Price to Sales stood at 30.52 in 2022, then dropped by 19.13% to 24.68 in 2023, then fell by 0.17% to 24.64 in 2024, then climbed by 2.02% to 25.13 in 2025, then retreated by 5.38% to 23.78 in 2026.
• The last three Price to Sales figures came in at 23.78 (Q3 2026), 19.41 (Q2 2026), and 21.77 (Q1 2026), per Business Quant data.